These efforts will prove useful for the design of next-generation small molecule inhibitors of PD-L1, with tailored physicochemical properties for making them resilient to drug-resistance mechanisms based on the acidification of the tumor microenvironment, as well as endowed with an improved safety profile. This evidence concerns the gene CD274 and neoplasm.